All In Biotech

Free tool

FAERS Monitor: Radicava Ors

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215446 or its brand name (Radicava Ors, Edaravone). Reports on generic versions are filed under their own applications.

Reports

1,604

Serious

1,191

74% of reports

Hospitalization

407

Death reported

462

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death212
  • cerebral infarction99
  • amyotrophic lateral sclerosis84
  • disease progression74
  • drug ineffective63
  • off label use53
  • dyspnoea51
  • muscular weakness50
  • fatigue45
  • pneumonia45
  • diarrhoea44
  • condition aggravated41
  • asthenia38
  • nausea34
  • gait disturbance33

Reports by year received

View as table
YearReports
20043
20053
20064
20073
20082
20094
20101
20113
201230
201325
201418
201522
201621
201745
201849
201976
202042
202156
2022103
2023194
2024363
2025319
2026218

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,555 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
amyotrophic lateral sclerosisSignal84532.1430.242,289
cerebral infarctionSignal9953.344.15,018
disease progressionSignal748.26.6463
muscular weaknessSignal505.84.4193
deathSignal2123.22.8337
gait disturbanceSignal332.31.622
pneumonia451.81.416
condition aggravated411.81.313
asthenia381.31.03
dyspnoea511.20.91
diarrhoea440.90.70
off label use530.80.63
fatigue450.80.63
drug ineffective630.60.515
nausea340.60.412

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.